Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 8/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233119 | 0.93 | HRH4 (0.40) | HRH4PTGESTLR8TLR7HRH3 | |
| Hydrochloric Acid SCHEMBL1233645 | 0.81 | NCF1 (0.44) | HRH4TLR8TLR7NCF1HTT | |
| SCHEMBL10123157 | 0.79 | HRH4 (0.39) | HRH4PTGESTLR8TLR7ACHE | |
| SCHEMBL1231771 | 0.77 | MCHR1 (0.50) | TLR7 | |
| Hydrochloric Acid SCHEMBL1232748 | 0.76 | MCHR1 (0.49) | TLR7 | |
| SCHEMBL2684172 | 0.76 | ALDH1A1 (0.39) | HRH4PTGESTLR8TLR7ACHE | |
| SCHEMBL2053271 | 0.76 | NPC1 (0.43) | HRH4ACHENCF1HTT | |
| SCHEMBL1232765 | 0.75 | HRH4 (0.39) | HRH4PTGESTLR8TLR7ACHE | |
| Hydrochloric Acid SCHEMBL1233122 | 0.75 | TLR7 (0.40) | TLR8TLR7ACHENCF1HTT | |
| SCHEMBL1232864 | 0.73 | HRH4 (0.38) | HRH4PTGESTLR8TLR7ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888349-B2 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | HRH4 55/4885PTGES 500/4885TLR8 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.